Andere Sprachen Prothena Corporation plc

Aktien

A1KAVV

IE00B91XRN20

PRTA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 29.04.2024			% 5 Tage	% 1. Jan.
21,19 ^USD	+1,53 %		-0,47 %	-41,69 %

04.03.	Prothena ernennt David Ford zum neu geschaffenen Chief People Officer	CI
21.02.	Prothena Corporation plc kündigt Änderungen im Vorstand an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia and Lymphoma	16.04.
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma	15.04.
Prothena : Director's Report and Financial Statements for Fiscal Year 2023	29.03.
Prothena to Participate in Upcoming Healthcare Conferences	05.03.
Prothena Names David Ford as Chief People Officer	04.03.
Prothena Appoints David Ford to Newly Created Chief People Officer Position	04.03.
Prothena Appoints David Ford to Newly Created Chief People Officer	04.03.
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate	21.02.
Prothena Corporation plc Announces Board Changes	21.02.
Sector Update: Health Care Stocks Gain Pre-Bell Friday	16.02.
Prothena Posts Q4 Net Loss as Revenue Slumps	15.02.
Prothena: Q4 Earnings Snapshot	15.02.
Earnings Flash (PRTA) PROTHENA CORPORATION Reports Q4 Revenue $316,000, vs. Street Est of $2.72M	15.02.
Prothena Corporation plc Provides Earnings Guidance for the Year 2024	15.02.
Prothena Corporation plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15.02.
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights	15.02.
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024	08.02.
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs	08.01.
Researchers return to Alzheimer's vaccines, buoyed by recent drug success	20.11.
Prothena: Q3 Earnings Snapshot	02.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Prothena Corporation plc

Aktien

A1KAVV

IE00B91XRN20

PRTA

Andere Sprachen

Filter